Alvin Shih
Directeur/Membre du Conseil chez ZEVRA THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Alvin Shih
Sociétés | Poste | Début | Fin |
---|---|---|---|
ZEVRA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 20/01/2024 | - |
Independent Dir/Board Member | 20/01/2024 | - | |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Directeur/Membre du Conseil | 04/02/2021 | - |
Directeur Général | 04/02/2021 | - | |
President | 04/02/2021 | - | |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Alvin Shih
Anciens postes connus de Alvin Shih
Sociétés | Poste | Début | Fin |
---|---|---|---|
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 22/07/2019 | 01/10/2020 |
Directeur Général | 22/07/2019 | 01/10/2020 | |
President | 22/07/2019 | - | |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Directeur Général | 01/11/2016 | 21/02/2019 |
TRAVERE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2014 | 31/10/2016 |
PFIZER, INC. | Directeur des opérations | 01/05/2010 | 01/05/2014 |
Formation de Alvin Shih
Vanderbilt University | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
The University of Alabama School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
Opérationnelle
Director/Board Member | 4 |
Chief Executive Officer | 3 |
President | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
TRAVERE THERAPEUTICS, INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
PFIZER, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Technology Services |
- Bourse
- Insiders
- Alvin Shih
- Expérience